metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Directly affiliated public institutions === China Cooperative Times Management Cadre College Technology Promotion Center Vocational Skills Appraisal and Guidance Center Information Center Audiovisual Center Commercial Printing Center Nanjing Institute for Comprehensive Utilization of Wild Plants Jinan Fruit Research Institute Hangzhou Tea Research Institute Zhengzhou Cotton and Hemp Engineering Technology Design and Research Institute Beijing Institute of Commercial Machinery Tianjin Institute of Renewable Resources Kunming Edible Fungi Research Institute Xi'an Institute of Lacquer Coatings
==== China ==== On May 12, the United States and China announced that tariffs would be reduced for a period of 90 days. U.S. tariffs on Chinese goods would be reduced from 145% to 30% and Chinese tariffs on U.S. goods would be reduced from 125% to 10%. However, this 30% is still more expensive for consumers in the United States compared to the state of affairs before Trump's initial tariffs. On August 11, 2025, this deal was extended for another 90 days.
Photograph 1. – Open rhinoplasty: The incisions are endonasal (in the nose), and thus are hidden. The skin-incision to the columella aids the plastic surgeon in precisely suturing to hide the scar—except for the columellar incision (red-dot guideline) across the nasal base. The columellar incision allows the surgeon to view the size, shape, and condition of the nasal cartilages and bones to be corrected. Photograph 2. – Open rhinoplasty: The nasal interior. The scissors indicate the lower lateral cartilage (blue), which is one of the wing-shaped cartilages that conform the tip of the nose. The jagged red delineation indicates the locale of the columellar incision. Once the skin has been lifted from the bone-and-cartilage framework, the surgeon performs the nasal correction tasks. Photograph 3. – Open rhinoplasty: To narrow the tip of a too-wide nose, the surgeon first determines the cause of the excess nasal width. The suture being emplaced will narrow the tip of the nose. The red delineation indicates the edge of the nose-tip cartilage, which is narrowed when the surgeon tightens the folded cartilage apex. The suture (light blue) ends in the needle (white); tweezers (green) hold the nasal cartilage in place for the suturing. Photograph 4. – Nasal hump excision: The black delineation indicates the desired nose-reduction outcome: a straight nose. The nasal hump is bone (red) above the scalloped grey line, and cartilage (blue) below the scalloped grey line.
Sources: en.wikipedia.org
The ratio of carbon isotopes in humans varies according to the types of plants digested with different photosynthesis pathways. The three photosynthesis pathways are C3 carbon fixation, C4 carbon fixation and Crassulacean acid metabolism. C4 plants are mainly grasses from tropical and subtropical regions, and are adapted to higher levels of radiation than C3 plants. Corn, millet and sugar cane are some well-known C4 crops, while trees and shrubs use the C3 pathway. C4 carbon fixation is more efficient when temperatures are high and atmospheric CO2 concentrations are low. C3 plants are more common and numerous than C4 plants as C3 carbon fixation is more efficient in a wider range of temperatures and atmospheric CO2 concentrations. The different photosynthesis pathways used by C3 and C4 plants cause them to discriminate differently towards 13C leading to distinctly different ranges of δ13C. C4 plants range between -9 and -16‰, and C3 plants range between -22 and -34‰. The isotopic signature of consumer collagen is close the δ13C of dietary plants, while apatite, a mineral component of bones and teeth, has an ~14‰ offset from dietary plants due fractionation associated with mineral formation. Stable carbon isotopes have been used as tracers of C4 plants in paleodiets. For example, the rapid and dramatic increase in 13C in human collagen after the adoption of maize agriculture in North America documents the transition from a C3 to a C4 (native plants to corn) diet by 1300 CE.
On 4 December 2024, the Lebanese Health Ministry reported that since 7 October 2023, Israeli attacks killed 4,047 people, including 316 children and 790 women, and injured 16,638 others. Among the dead were at least 41 Lebanese Army soldiers and more than 200 medics. Several UNIFIL workers and peacekeepers were injured in numerous attacks by both Israel and Lebanese militias. By 25 November 2025, the Lebanese Health Ministry reported that Israeli attacks during the ceasefire had killed 331 people and injured 945. The UN said that at least 127 fatalities were civilians. At the height of the conflict in October 2024, more than 1.2 million Lebanese were displaced, including between 200,000 and 300,000 who fled into Syria.
Since the fraction of nuclides decaying per unit of time is inversely proportional to an isotope's half-life, the relative radioactivity of the lesser amount of human-produced radioisotopes (thousands of tons instead of trillions of tons) would diminish once the isotopes with far shorter half-lives than the bulk of natural radioisotopes decayed. In January 2013, Cumbria county council rejected UK central government proposals to start work on an underground storage dump for nuclear waste near to the Lake District National Park. "For any host community, there will be a substantial community benefits package and worth hundreds of millions of pounds" said Ed Davey, Energy Secretary, but nonetheless, the local elected body voted 7–3 against research continuing, after hearing evidence from independent geologists that "the fractured strata of the county was impossible to entrust with such dangerous material and a hazard lasting millennia." Horizontal drillhole disposal describes proposals to drill over one km vertically, and two km horizontally in the earth's crust, for the purpose of disposing of high-level waste forms such as spent nuclear fuel, Caesium-137, or Strontium-90. After the emplacement and the retrievability period, drillholes would be backfilled and sealed. A series of tests of the technology were carried out in November 2018 and then again publicly in January 2019 by a U.S. based private company. The test demonstrated the emplacement of a test-canister in a horizontal drillhole and retrieval of the same canister.
=== Insulin glargine === Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects typically begin within an hour of injection. Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain. NPH insulin is generally preferred over insulin glargine during pregnancy. After injection, microcrystals gradually release insulin over a period of approximately 24 hours. This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver. Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes. Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi and Viatris.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.